Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Imagion Biosystems Ltd. ( (AU:IBX) ).
Imagion Biosystems Ltd. announced the cessation of 25,000 performance rights due to the expiry of options or other convertible securities without exercise or conversion as of November 30, 2025. This announcement may impact the company’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market positioning.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems Ltd. operates in the biotechnology industry, focusing on the development of diagnostic imaging technologies. The company is known for its innovative approaches to cancer detection and other medical imaging applications.
Average Trading Volume: 6,865,767
Technical Sentiment Signal: Sell
Current Market Cap: A$9.56M
For an in-depth examination of IBX stock, go to TipRanks’ Overview page.